[Meta-analysis on indirect comparison of Fuzheng Huayu Jiaonang and Anluo Huaxian Wan in treatment of chronic hepatitis B with liver fibrosis].

To investigate the efficacy and safety of Fuzheng Huayu Jiaonang (FZ) and Anluo Huaxian Wan (AL) in the treatment of chronic hepatitis B liver fibrosis. Jadad scoring method was adopted to evaluate the quality of literature, Rev Man 5.3 software was used for Meta-analysis, and indirect comparison was carried out by ITC software. The randomized controlled trials (RCTs) were collected for comparing FZ and AL in treatment of chronic hepatitis B with liver fibrosis. With ETV as the common control, they were compared through indirect Meta-analysis (ITC). Finally, 15 articles (10 FZ, 5 AL) involving 1 316 patients were included. According to the indirect comparison, FZ combined with ETV had significant improvements in hyaluronic acid, laminin, procollagen type Ⅲ, and collagen type Ⅳ. AL combined with ETV had significant improvements in laminin, procollagen type Ⅲ, collagen type Ⅳ, but with no difference in hyaluronic acid. The safety of AL was higher than that of FA. The limited evidences in this study showed that Anluo Huaxian Wan had a higher safety than Fuzheng Huayu Jiaonang, but a lower total efficiency. Due to the low quality of the included RCTs, these two medicines shall be comprehensively compared in further high-quality clinical trials.